COMPANY PROFILE // THE 014 REPORT
Bausch Health Companies Inc.
BHC (NYSE) · Formerly: Valeant Pharmaceuticals International, Inc.; BIOVAIL Corp; BIOVAIL CORP INTERNATIONAL; BIOVAIL CORPORATION INTERNATIONAL
Assembled from 1 government source in 3.5 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Bausch Health Companies Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NJ, based in Quebec, Quebec, Canada; listed as BHC (NYSE).[source] It reported revenue of $10.27 billion for the fiscal year ended 2025-12-31.[source] It has filed 66 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-10-29.[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- APPIO THOMAS · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Carson Seana · EVP, General Counsel (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Charhon Jean-Jacques · EVP, CFO (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- LEE STEVEN HYOSIG · SVP, Controller & CAO (Officer) · latest Form 4 2026-02-27 · filing · LinkedIn search
- Lenar Aimee J. · EVP, US Pharma (Officer) · latest Form 4 2026-02-27 · filing · LinkedIn search
- GOETTLER MICHAEL · Director · latest Form 4 2025-07-29 · filing · LinkedIn search
- Garcia Christian A · Director · latest Form 4 2025-05-20 · filing · LinkedIn search
- ICAHN BRETT · Director · latest Form 4 2025-07-02 · filing · LinkedIn search
- KAVANAGH SARAH B · Director · latest Form 4 2025-05-20 · filing · LinkedIn search
- LEUNG SANDRA · Director · latest Form 4 2026-01-02 · filing · LinkedIn search
- Lee Frank D. · Director · latest Form 4 2025-08-22 · filing · LinkedIn search
- Miller Steven D · Director · latest Form 4 2025-05-20 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000885590 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 2150 ST. ELZEAR BLVD. WEST, QUEBEC, A8, H7L 4A8 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- DANA Inc · Garcia Christian A
- TETRA TECHNOLOGIES INC · Garcia Christian A
- Mueller Water Products, Inc. · Garcia Christian A
- DANA Inc · ICAHN BRETT
- INTERNATIONAL FLAVORS & FRAGRANCES INC · ICAHN BRETT
- SANDRIDGE ENERGY INC · ICAHN BRETT
- CVR ENERGY INC · ICAHN BRETT
- Bausch & Lomb Corp · ICAHN BRETT
- Bausch & Lomb Corp · KAVANAGH SARAH B
- Pacira BioSciences, Inc. · Lee Frank D.
- JETBLUE AIRWAYS CORP · Miller Steven D
- INTERNATIONAL FLAVORS & FRAGRANCES INC · Mulligan Richard
- Sana Biotechnology, Inc. · Mulligan Richard
- Acadian Asset Management Inc. · Paulson John
- Bausch & Lomb Corp · Paulson John
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-10-29 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-28 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-19 filing 144 · SEC EDGAR
- 2026-07-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-01 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-06-01 filing SD · SEC EDGAR
- 2026-05-19 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-19 filing 144 · SEC EDGAR
- 2026-04-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-08 filing ARS · SEC EDGAR
- 2026-04-08 filing DEFA14A · SEC EDGAR
- 2026-04-08 filing Proxy statement · SEC EDGAR
- 2026-03-03 filing 144 · SEC EDGAR
- 2026-03-02 officer change 8-K items 5.02 · SEC EDGAR
- 2026-03-02 filing 144 · SEC EDGAR
- 2026-02-27 filing 144 · SEC EDGAR
- 2026-02-27 insider First Form 3/4/5 on record for Charhon Jean-Jacques (EVP, CFO) · SEC Forms 3/4/5
- 2026-02-19 filing Annual report (10-K) · SEC EDGAR
- 2026-02-18 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-11 insider First Form 3/4/5 on record for APPIO THOMAS (Chief Executive Officer) · SEC Forms 3/4/5
- 2026-01-23 filing 8-K items 7.01 · SEC EDGAR
- 2026-01-13 filing 8-K items 2.02,7.01 · SEC EDGAR
- 2026-01-02 filing 8-K items 1.01,2.03,8.01,9.01 · SEC EDGAR
- 2025-12-29 filing 8-K items 1.01,2.03,9.01 · SEC EDGAR
- 2025-12-23 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-12-12 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-12-09 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2025-11-24 filing 8-K items 8.01,9.01 · SEC EDGAR
154 earlier entries
- 2025-10-30 filing Quarterly report (10-Q)
- 2025-10-29 filing 8-K items 2.02,9.01
- 2025-10-09 filing 8-K items 5.07
- 2025-09-11 filing 8-K items 8.01,9.01
- 2025-09-11 filing SC TO-T/A
- 2025-09-08 filing 144
- 2025-09-08 insider First Form 3/4/5 on record for Carson Seana (EVP, General Counsel)
- 2025-08-27 filing Proxy statement
- 2025-08-26 filing SC TO-T/A
- 2025-08-21 filing 144
- 2025-08-15 officer change 8-K items 1.02,5.02,7.01,9.01
- 2025-08-15 filing SCHEDULE 13D/A
- 2025-08-14 filing SCHEDULE 13D/A
- 2025-08-13 filing PRE 14A
- 2025-08-12 filing SC TO-T
- 2025-07-31 filing S-8
- 2025-07-31 filing SC TO-C
- 2025-07-31 filing Quarterly report (10-Q)
- 2025-07-30 filing SC TO-C
- 2025-07-30 filing 8-K items 2.02,9.01
- 2025-07-29 filing SC TO-C
- 2025-07-29 filing SC TO-C
- 2025-07-29 filing 8-K items 8.01,9.01
- 2025-07-29 insider First Form 3/4/5 on record for GOETTLER MICHAEL (Director)
- 2025-07-29 insider First Form 3/4/5 on record for LEUNG SANDRA (Director)
- 2025-07-24 officer change 8-K items 5.02,7.01,9.01
- 2025-07-16 insider First Form 3/4/5 on record for Lenar Aimee J. (EVP, US Pharma)
- 2025-07-15 insider First Form 3/4/5 on record for LEE STEVEN HYOSIG (SVP, Controller & CAO)
- 2025-07-10 officer change 8-K items 5.02,7.01,9.01
- 2025-06-27 filing 8-K items 1.01,2.03,8.01,9.01
- 2025-06-18 filing 8-K items 8.01,9.01
- 2025-06-17 filing SCHEDULE 13D/A
- 2025-06-10 filing 8-K items 8.01,9.01
- 2025-05-30 filing SD
- 2025-05-21 filing SCHEDULE 13D/A
- 2025-05-21 filing SCHEDULE 13D/A
- 2025-05-21 filing 8-K items 1.01,9.01
- 2025-05-20 insider First Form 3/4/5 on record for Garcia Christian A (Director)
- 2025-05-20 insider First Form 3/4/5 on record for KAVANAGH SARAH B (Director)
- 2025-05-20 insider First Form 3/4/5 on record for Lee Frank D. (Director)
- 2025-05-20 insider First Form 3/4/5 on record for Miller Steven D (Director)
- 2025-05-20 insider First Form 3/4/5 on record for Mulligan Richard (Director)
- 2025-05-20 insider First Form 3/4/5 on record for POWER ROBERT N (Director)
- 2025-05-15 officer change 8-K items 5.02
- 2025-05-14 filing 8-K items 5.07
- 2025-05-01 filing Quarterly report (10-Q)
- 2025-04-30 filing 8-K items 2.02,9.01
- 2025-04-22 filing DEFA14A
- 2025-04-17 filing CERT
- 2025-04-15 filing 8-K items 1.01,3.03,7.01,9.01
- 2025-04-15 filing 8-A12B
- 2025-04-09 filing 8-K items 1.01,2.03,9.01
- 2025-04-07 filing SCHEDULE 13D
- 2025-04-02 filing ARS
- 2025-04-02 filing DEFA14A
- 2025-04-02 filing Proxy statement
- 2025-04-01 insider First Form 3/4/5 on record for ICAHN BRETT (Director)
- 2025-04-01 insider First Form 3/4/5 on record for Paulson John (Director)
- 2025-04-01 insider First Form 3/4/5 on record for WECHSLER AMY B (Director)
- 2025-03-25 filing 8-K items 8.01,9.01
- 2025-03-19 filing 8-K items 8.01,9.01
- 2025-02-20 filing Annual report (10-K)
- 2025-02-19 filing 8-K items 2.02,9.01
- 2024-12-02 filing 144
- 2024-11-01 filing 8-K items 1.01,2.03,9.01
- 2024-10-31 filing Quarterly report (10-Q)
- 2024-10-30 filing 8-K items 2.02,9.01
- 2024-09-20 filing SD
- 2024-09-06 filing 144
- 2024-08-19 filing SC 13D/A
- 2024-08-01 filing S-8
- 2024-08-01 filing Quarterly report (10-Q)
- 2024-08-01 filing 8-K items 2.02,9.01
- 2024-07-19 officer change 8-K items 5.02,7.01,9.01
- 2024-05-15 filing 8-K items 5.07
- 2024-05-02 filing Quarterly report (10-Q)
- 2024-05-02 filing 8-K items 2.02,9.01
- 2024-04-04 filing ARS
- 2024-04-04 filing DEFA14A
- 2024-04-04 filing Proxy statement
- 2024-03-04 filing 144
- 2024-02-22 filing Annual report (10-K)
- 2024-02-22 filing 8-K items 2.02,9.01
- 2024-02-07 filing SC 13D/A
- 2024-02-01 officer change 8-K items 5.02,7.01,9.01
- 2023-12-05 filing 144
- 2023-11-13 filing 8-K/A items 9.01
- 2023-11-06 filing 144
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,9.01
- 2023-09-29 filing 8-K items 1.01,2.01,2.03,9.01
- 2023-09-29 officer change 8-K/A items 5.02,9.01
- 2023-09-18 officer change 8-K items 5.02,7.01,9.01
- 2023-09-14 filing 8-K items 8.01
- 2023-09-11 filing 8-K items 7.01,8.01,9.01
- 2023-09-06 filing 8-K items 7.01,9.01
- 2023-09-06 filing 144
- 2023-08-03 filing S-8
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-07-19 filing SD
- 2023-07-07 filing 8-K items 1.01,9.01
- 2023-07-07 filing 8-K items 1.01,2.03,7.01,9.01
- 2023-06-30 filing 8-K items 8.01,9.01
- 2023-05-17 filing 8-K items 5.07
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-04-06 filing ARS
- 2023-04-06 filing DEFA14A
- 2023-04-06 filing Proxy statement
- 2023-03-06 filing 144
- 2023-03-01 officer change 8-K items 5.02,7.01,9.01
- 2023-02-23 filing Annual report (10-K)
- 2023-02-23 filing 8-K items 2.02,9.01
- 2023-02-15 filing 8-K items 7.01
- 2022-11-30 filing 8-K items 8.01,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-10-04 filing 8-K items 1.01,2.03,9.01
- 2022-09-28 filing 8-K items 8.01,9.01
- 2022-09-15 filing 8-K items 8.01,9.01
- 2022-09-12 officer change 8-K items 5.02
- 2022-09-02 filing 10-Q/A
- 2022-08-31 filing 8-K items 7.01,9.01
- 2022-08-22 filing 8-K items 8.01,9.01
- 2022-08-09 filing S-8
- 2022-08-09 filing Quarterly report (10-Q)
- 2022-08-09 filing 8-K items 2.02,9.01
- 2022-07-29 filing 8-K items 8.01,9.01
- 2022-07-20 filing 8-K items 7.01
- 2022-06-24 officer change 8-K items 5.02,9.01
- 2022-06-24 officer change 8-K items 5.02,5.07
- 2022-06-21 filing 8-K items 7.01,9.01
- 2022-06-15 filing DEFA14A
- 2022-06-03 officer change 8-K items 5.02
- 2022-06-02 filing SD
- 2022-05-31 officer change 8-K items 5.02
- 2022-05-13 filing SC 13D/A
- 2022-05-11 filing 8-K items 8.01,9.01
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 1.01,8.01,9.01
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-05-02 filing DEFA14A
- 2022-05-02 filing Proxy statement
- 2022-04-28 filing 8-K items 1.01,2.02,8.01,9.01
- 2022-04-25 filing 8-K items 7.01
- 2022-04-18 filing 8-K items 7.01
- 2022-04-04 filing 8-K items 8.01
- 2022-03-31 filing 8-K items 1.01,9.01
- 2022-03-14 filing 8-K items 7.01
- 2018-07-03 name change Name changed from Valeant Pharmaceuticals International, Inc.
- 2010-09-27 name change Name changed from BIOVAIL Corp
- 2010-04-07 name change Name changed from BIOVAIL CORP INTERNATIONAL
- 2001-01-05 name change Name changed from BIOVAIL CORPORATION INTERNATIONAL
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-10-29 (within 30 days) 10-Q filed
- 2026-10-28 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-30 (older) 10-Q filed
- 2026-07-29 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-01 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-01 (older) SD filed
- 2026-05-19 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-04-30 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NYSE:BHC The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above; 5 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 885590 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | BHC / NYSE | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
former name (shown apart, not merged) (5)
- former nameBiovail Corporation · DOJ and agency corporate enforcement
- former nameBiovail Corporation · DOJ and agency corporate enforcement
- former nameValeant Pharmaceuticals International, Inc · DOJ and agency corporate enforcement
- former nameValeant Pharmaceuticals International, Inc · DOJ and agency corporate enforcement
- former nameVALEANT PHARMACEUTICALS INTERNATIONAL · State licences
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $10,266,000,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 00:19 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $157,000,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:19 UTC | Report an error |
| Total assets (at 2025-12-31) | $26,366,000,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:19 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$554,000,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:19 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $1,309,000,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:19 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
| State of incorporation | NJ | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
| Business address | 2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC, A8, H7L 4A8 | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
| Exchanges | NYSE | 2026-10-29 | SEC EDGAR company profile | as filed | 2026-11-21 00:19 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $1,400,000,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:19 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $397,000,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 00:19 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $20,817,000,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 00:19 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $228,000,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:19 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0000885590-26-000123
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $2,941,000,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Net income (loss) | $436,000,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Interest expense | $398,000,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Cash and cash equivalents | $2,485,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due in the next 12 months | $701,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due in year 2 | $3,766,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due in year 3 | $1,667,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due in year 4 | $4,123,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due in year 5 | $3,896,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
| Debt due after year 5 | $6,000,000,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0000885590-26-000123 | 2026-11-21 00:19 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-10-29 Filing 10-Q filed
- 2026-10-28 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-30 Filing 10-Q filed
- 2026-07-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-01 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-01 Filing SD filed
- 2026-05-19 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-04-30 Filing 10-Q filed
- 2026-04-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-08 Filing ARS filed
- 2026-04-08 Filing DEFA14A filed
- 2026-04-08 Filing DEF 14A filed
- 2026-03-02 Filing 8-K filed: Item 5.02 officer or director change
- 2026-02-19 Filing 10-K filed
- 2026-02-18 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-23 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-01-13 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure
- 2026-01-02 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 8.01 other event; Item 9.01 exhibits
- 2025-12-29 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2025-12-23 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-12-12 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-12-09 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-11-24 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-10-30 Filing 10-Q filed
- 2025-10-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-10-28 8-K Item 2.02, Results of Operations and Financial Condition
On October 28, 2026, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended September 30, 2026 and certain other financial information as of and for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy any securities. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the… the 8-K · retrieved 2026-11-21 00:19 UTC - 2026-07-29 8-K Item 2.02, Results of Operations and Financial Condition
On July 29, 2026, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended June 30, 2026 and certain other financial information as of and for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy any securities. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities… the 8-K · retrieved 2026-11-21 00:19 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/885590.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000885590. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.